NCT05298696

Efficacy of Cilostazol in Prevention of Peripheral Neuropathy

Safety and Efficacy of Cilostazol in Prevention of Paclitaxel Induced Peripheral Neuropathy in Breast Cancer Patients

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 71 (actual)
• Sponsor: Mansoura University · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

There are several mechanisms concerning pathophysiology of paclitaxel induced peripheral neuropathy. One of the main mechanisms is induction of Schwann cell dedifferentiation by paclitaxel. At the preclinical level, cilostazol potently inhibited paclitaxel-induced dedifferentiation of cultured Schwann cells, yet this positive effect have not been clinically investigated.

Conditions

• Peripheral Neuropathy
• Breast Cancer

Interventions

Type	Name	Description
DRUG	Cilostazol	Cilostazol 100 mg twice daily
DRUG	Placebo	Placebo twice daily

Timeline

• Start date: 2022-03-28
• Primary completion: 2022-10-30
• Completion: 2022-12-30
• First posted: 2022-03-28
• Last updated: 2023-03-15

Locations

1 site across 1 country: Egypt